fda.gov
- Reputation Factor
-
2.7
High
Wikipedia citation breadth, not editorial reliability. One citing article gives 1.0; 100 gives 2.5; and 10,000 gives 3.25. More articles increase the multiplier toward 4.0 with diminishing returns; hostname count does not affect it.
- Sites Owned
- 7
- Total Reference Links
- 291
- Total Citations
- 374
- Unique Wikipedia Articles Citing
- 265
Associated Sites
Top Reference Links
| Score | Article | Site | Category | Cited In (Articles) |
|---|---|---|---|---|
| 56.8 |
Novel Drug Approvals for 2025https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025 |
www.fda.gov | Uncategorized | 21 |
| 40.6 |
Novel Drug Approvals for 2026https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026 |
www.fda.gov | Uncategorized | 15 |
| 16.2 |
FDA Responds to Evidence of Possible Association Between Autism and Acetaminophen Use During Pregnancyhttps://www.fda.gov/news-events/press-announcements/fda-responds-evidence-possible-association-between-autism-and-acetaminophen-use-during-pregnancy |
www.fda.gov | Uncategorized | 6 |
| 13.5 |
FDA warning letters (search "elderberry" by years)https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters |
www.fda.gov | Uncategorized | 5 |
| 10.8 |
FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type Ahttps://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-pediatric-patients-sanfilippo-syndrome-type |
www.fda.gov | Uncategorized | 4 |
| 10.8 |
FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Iahttps://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-aged-8-years-and-older-glycogen-storage-disease-type-ia |
www.fda.gov | Uncategorized | 4 |
| 8.1 |
FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Orderhttps://www.fda.gov/news-events/press-announcements/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order |
www.fda.gov | Uncategorized | 3 |
| 8.1 |
FDA Approves Treatment for Fibrodysplasia Ossificans Progressivahttps://www.fda.gov/drugs/news-events-human-drugs/fda-approves-second-treatment-fibrodysplasia-ossificans-progressiva |
www.fda.gov | Uncategorized | 3 |
| 8.1 |
FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancerhttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lurbinectedin-combination-atezolizumab-or-atezolizumab-and-hyaluronidase-tqjs-extensive |
www.fda.gov | Uncategorized | 3 |
| 8.1 |
FDA Approves First Gene Therapy for Severe leukocyte adhesion deficiency type Ihttps://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-severe-leukocyte-adhesion-deficiency-type-i |
www.fda.gov | Uncategorized | 3 |